Home-Logo
left-arrow
person

Prof Oliver Rackham

Diagnostic and Therapeutic Sciences

Synthetic Biology and Gene Therapy

Professor Oliver Rackham leads a research team dedicated to advancing synthetic biology to engineer and understand transcriptomes, genomes, and organelles. He established his research group in Western Australia in 2006 as an NHMRC Peter Doherty Fellow, and has since been recognised with a Wenner-Gren Foundation Fellowship, an ARC Future Fellowship, and the Marshall Medal. A founding member and former President of Synthetic Biology Australasia, Professor Rackham joined Curtin University and the Curtin Medical Research Institute in 2019. His pioneering work applies genomic technologies and synthetic biology to explore and reprogramme gene expression, described by Faculty of 1000 as one of the “seminal achievements for synthetic biology”. This research also led to his induction into the European Inventor Hall of Fame.  


About

Professor Oliver Rackham’s research focuses on engineering and understanding mammalian gene expression through the application of synthetic biology and genomic technologies. His team develops innovative tools and therapeutic strategies to address cancer, mitochondrial disorders, and other rare diseases.

Synthetic biology, a rapidly evolving field that enables the programming of molecules and cells with novel functions, underpins much of his group’s work. The team has pioneered advances at the post-transcriptional level of gene expression, creating powerful genetic methods to manipulate genes and engineering the first universal codes for RNA recognition. These breakthroughs are now being translated into next-generation gene therapies for diseases that are currently incurable or difficult to treat.

 

Research Focus

Professor Oliver Rackham’s research focuses on synthetic biology and genomic engineering to understand and control mammalian gene expression. His work aims to develop novel genetic tools and gene therapies for cancer, mitochondrial disorders, and rare diseases, with a particular emphasis on post-transcriptional regulation and RNA recognition.

 

Research Team

Dr Andrianto Gandadireja

Research Associate

Dr Cristiana Zollo

Research Associate

Richard Lee

Sessional Academic

Dr Srikanth Kompella

Senior Data Scientist

Anjaëlle Chopin

PhD Student

Jade Waters

PhD Student

Linn Anderson

Honours Student

Publications

ABSTRACT

A genome-wide knockout screen identified members of the SLC25 family of mitochondrial carrier proteins as important regulators of the rate of de novo mitochondrial protein synthesis. To elucidate this relationship, we generated human cell knockouts for SLC25A25, SLC25A44, SLC25A45, and SLC25A48, which have been shown to exchange adenosine triphosphate-magnesium (ATP-Mg) and phosphate, branched-chain amino acids, methylated basic amino acids, and choline, respectively. Multiomic and functional analyses identified that these four carriers are crucial for mitochondrial translation, biogenesis and function of the oxidative phosphorylation system, as well as mitochondrial morphology. Thermostability screens showed that SLC25A48 is specifically stabilized by choline, and changes in the mitochondrial metabolome and lipidome indicated defects in choline biosynthetic pathways and remodeling of mitochondrial membranes, both consistent with SLC25A48 being a choline transporter. These results highlight the essential roles of specific SLC25 transporters in maintaining mitochondrial structure and function and show that impaired transport of branched-chain amino acids, methylated basic amino acids, ATP-Mg, and choline affects mitochondrial translation.

Rudler, D. L., L. A. Hughes, M. S. King, J. Baker, R. G. Lee, A. P. Gandadireja, A. Sunil, S. V. Fagan, B. Payne, N. Gray, and 4 more contributors. 2026. Specific SLC25 carriers regulate mitochondrial protein synthesis.Science Advances 12 (9)

Find a researcher

Search for researchers at Curtin MRI

Search by name

Search by area of research